JP2005525085A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525085A5
JP2005525085A5 JP2003540322A JP2003540322A JP2005525085A5 JP 2005525085 A5 JP2005525085 A5 JP 2005525085A5 JP 2003540322 A JP2003540322 A JP 2003540322A JP 2003540322 A JP2003540322 A JP 2003540322A JP 2005525085 A5 JP2005525085 A5 JP 2005525085A5
Authority
JP
Japan
Prior art keywords
hiv
antigen
host
recombinant adenovirus
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003540322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525085A (ja
Filing date
Publication date
Priority claimed from US10/003,035 external-priority patent/US20020155127A1/en
Application filed filed Critical
Publication of JP2005525085A publication Critical patent/JP2005525085A/ja
Publication of JP2005525085A5 publication Critical patent/JP2005525085A5/ja
Pending legal-status Critical Current

Links

JP2003540322A 2001-11-01 2002-11-01 ヒト免疫不全ウイルスに対する遺伝子ワクチン Pending JP2005525085A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/003,035 US20020155127A1 (en) 2000-06-02 2001-11-01 Genetic vaccine against human immunodeficiency virus
PCT/US2002/035112 WO2003038057A2 (en) 2001-11-01 2002-11-01 Genetic vaccine against human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2005525085A JP2005525085A (ja) 2005-08-25
JP2005525085A5 true JP2005525085A5 (https=) 2006-01-05

Family

ID=21703782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003540322A Pending JP2005525085A (ja) 2001-11-01 2002-11-01 ヒト免疫不全ウイルスに対する遺伝子ワクチン

Country Status (9)

Country Link
US (2) US20020155127A1 (https=)
EP (1) EP1451329A4 (https=)
JP (1) JP2005525085A (https=)
KR (1) KR20050042458A (https=)
CN (1) CN1636063A (https=)
CA (1) CA2465037A1 (https=)
HK (1) HK1077601A1 (https=)
WO (1) WO2003038057A2 (https=)
ZA (1) ZA200403434B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
WO2005012538A2 (en) 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Accelerated vaccination
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2006050394A2 (en) * 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
KR101441843B1 (ko) * 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
WO2007055952A2 (en) * 2005-11-03 2007-05-18 Wyeth Process for producing stable hiv th-ctl peptides
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
WO2007134325A2 (en) * 2006-05-15 2007-11-22 Introgen Therapeutics, Inc. Methods and compositions for protein production using adenoviral vectors
WO2008086386A2 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
AU2008352966C1 (en) * 2007-12-18 2014-09-25 Boston Medical Center Corporation Pre- or post-exposure treatment for filovirus or arenavirus infection
US20110217328A1 (en) * 2007-12-18 2011-09-08 Trustees Of Boston University Compositions and methods for treating ebola virus infection
WO2009111738A2 (en) * 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
WO2009120306A1 (en) * 2008-03-25 2009-10-01 Trustees Of Boston University Multivalent vaccine vector for the treatment and inhibition of viral infection
US10071154B2 (en) 2008-04-04 2018-09-11 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CN101591379B (zh) 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2603799A4 (en) 2010-08-12 2014-02-12 Clontech Lab Inc SIDEFLOW ASSAYS FOR NON-DIAGNOSTIC ANALYSIS
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CA2861335A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
CN104995299B (zh) * 2012-12-11 2020-02-28 宝生物工程株式会社 表达盒
GB201301119D0 (en) * 2013-01-22 2013-03-06 Vaxxit Srl Viral vaccines
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
AU2014359085B2 (en) * 2013-12-08 2017-11-02 Peptcell Limited HIV antigens and antibodies and compositions, methods and uses thereof
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN107149675A (zh) * 2016-03-10 2017-09-12 广东思峰生物科技有限责任公司 一种白细胞介素-12的新用途
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN108823232A (zh) * 2018-04-20 2018-11-16 中国科学院广州生物医药与健康研究院 一种艾滋病疫苗及其制备方法
RU2722648C2 (ru) * 2018-11-16 2020-06-02 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ проверки иммуногенности вакцинных антигенов для получения высокоэффективных вакцин против опасных инфекций
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN111117974B (zh) * 2019-12-20 2022-02-22 华南农业大学 一种可视化绿色荧光猪伪狂犬病毒及其构建方法
WO2024048793A1 (ja) * 2022-09-02 2024-03-07 国立研究開発法人医薬基盤・健康・栄養研究所 感染を治療するための弱毒化ウイルス
CN119390828A (zh) * 2024-12-31 2025-02-07 天津龙晟生物科技有限公司 人类免疫缺陷病毒hiv抗体及其应用和其检测产品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
AU2678797A (en) * 1996-04-22 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Heterologous boosting immunizations
CA2378539A1 (en) * 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes

Similar Documents

Publication Publication Date Title
JP2005525085A5 (https=)
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Grubman Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals
Yang et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting
Du et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
JP2009511084A5 (https=)
JP2020528911A5 (https=)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
JP2004527264A5 (https=)
JP2017515508A5 (https=)
JP2013241442A5 (https=)
WO2006044923A3 (en) Yeast-based therapeutic for chronic hepatitis c infection
JP2014503206A5 (https=)
JP2009515831A5 (https=)
Cobleigh et al. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose
JP2019505560A5 (https=)
WO2004004761A3 (en) Adjuvant viral particle
JP2004500366A5 (https=)
JPWO2022009121A5 (https=)
JP2022172244A5 (https=)
Saeedi et al. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice
NO20074855L (no) Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler
Fiedler et al. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine
JP2020537526A5 (https=)